Budesonide oral suspension is set to be the first FDA approved treatment for eosninophilic esophagitis. Takeda pharmaceuticals is the manufacturer of the drug. Eosinophilic esophagitis (EoE) is a chronic, immune-mediated, inflammatory disease localized in the esophagus. The prevalence of EoE is rising. Approximately 1 in 2000 people in the US live with EoE. EoE is […]
Future Eosinophilic Esophagitis Treatment Options
Future eosinophilic esophagitis treatments are currently in development. There are currently on FDA approved medications for the treatment of EoE. Commonly used treatments now are proton pump inhibitors, swallowed or topical corticosteroids and food elimination diets. Although each of these options is effective, there are limitations. Swallowed steroids can control inflammation 70-80% of the time, […]
Eosinophilic Esophagitis (EoE) Treatment
Eosinophilic esophagitis (EoE) is an eosinophilic rich gastrointestinal/allergy disease increasing in pediatrics and adults worldwide. The diagnosis requires greater than or equal to 15 eosinophils per high-power field on light microscopy after a biopsy. Symptoms reflect esophageal dysfunction, and typical endoscopic features include linear furrows, white plaques, and concentric rings. Progressive disease leads to tissue […]